Patrick Darken

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Molecular Dynamics Simulations

Quality Control

Top Venues

Clinical trials (London, England)

International journal of chronic obstructive pulmonary disease

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies. Clinical trials (London, England) 21 (2) (2023)
Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies. Clinical trials (London, England) 21 (2) (2023)
Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies. Clinical trials (London, England) 21 (2) (2023)
Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies. Clinical trials (London, England) (2023)
Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies. Clinical trials (London, England) 21 (2) (2023)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Fernando J Martinez, Gary T Ferguson, Eric Bourne, Shaila Ballal, Patrick Darken, Magnus Aurivillius, Paul Dorinsky, Colin Reisner
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. International journal of chronic obstructive pulmonary disease 16 (2021)
Patrick Darken, Jack Nyberg, Shaila Ballal, David Wright
The attributable estimand: A new approach to account for intercurrent events. Pharmaceutical statistics 19 (5) (2020)